Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune diseases. Their proprietary immune tolerance platform features proteins engineered to deliver precise, targeted disease therapy without the side effects of broad immunosuppression. By specifically targeting autoreactive cells for removal while leaving healthy immune cells untouched, Anokion's approach aims to transform treatment for autoimmune patients worldwide. Founded in Switzerland and based on innovation from EPFL Life Sciences, Anokion is led by a diverse team of entrepreneurial scientists and experienced industry professionals.
Didier Trono, Céline Pellaton, Madeleine Suffiotti